FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384694709> ?p ?o ?g. }

• W4384694709 abstract "Sorafenib included in Chinese medical insurance is the earliest targeted drug for radioactive iodine refractory differentiated thyroid cancer (RR-DTC). This study is to further demonstrate the clinical efficacy and safety of sorafenib used in Zhujiang Hospital of Southern Medical University.RR-DTC patients treated at our Department of Nuclear Medicine in Zhujiang Hospital of Southern Medical University (October 2017-May 2020) were retrospectively analyzed. Treatment effects, progression-free survival (PFS), and adverse effects (AEs) during medication were evaluated.Of the 31 patients included, 26 patients were evaluated for efficacy with a median follow-up time of 17.5 months (4.0-51.0 months). The disease control rate (DCR) was 57.7% (n = 15) and the objective response rate (ORR) was 26.9% (n = 7). Most patients with disease control had thyroglobulin decreases of more than 60% (p = 0.004), ORRs were favorable in patients with lung metastasis and lung-only metastasis (p = 0.010 and 0.001, respectively). The PFS of the 26 patients analyzed was 16.5 months (95%CI: 14.41 -23.90 months). In the subgroup analysis, female, patients with lung-only metastasis, hand-foot skin syndrome (HFS), and thyroglobulin response ≥ 60% observed longer PFS (p = 0.038, 0.045, 0.035, and 0.000, respectively), while patients with bone metastasis had lower PFS (p = 0.035). The most common toxicity profile was HFS (93.5%), followed by diarrhea (83.9%), alopecia (74.2%). All the side effects were mainly grade 1-2. Grade 3-4 adverse reactions were more common in diarrhea and HFS.Sorafenib has promising efficacy in RR-DTC, especially in patients with lung metastasis and lung-only metastasis. The AEs of sorafenib were generally mild, and the main AE was HFS." @default.
• W4384694709 created "2023-07-20" @default.
• W4384694709 creator A5001822422 @default.
• W4384694709 creator A5010319430 @default.
• W4384694709 creator A5013208204 @default.
• W4384694709 creator A5036731044 @default.
• W4384694709 creator A5040352781 @default.
• W4384694709 creator A5041033720 @default.
• W4384694709 creator A5052434379 @default.
• W4384694709 creator A5062584900 @default.
• W4384694709 creator A5069299119 @default.
• W4384694709 date "2023-07-18" @default.
• W4384694709 modified "2023-09-25" @default.
• W4384694709 title "The efficacy and safety in radioactive iodine refractory thyroid cancer patients treated with sorafenib" @default.
• W4384694709 cites W1604548454 @default.
• W4384694709 cites W1967624469 @default.
• W4384694709 cites W1982618742 @default.
• W4384694709 cites W1990095055 @default.
• W4384694709 cites W1997533142 @default.
• W4384694709 cites W1999225131 @default.
• W4384694709 cites W2000292756 @default.
• W4384694709 cites W2013548700 @default.
• W4384694709 cites W2019607817 @default.
• W4384694709 cites W2036045317 @default.
• W4384694709 cites W2040642592 @default.
• W4384694709 cites W2055600128 @default.
• W4384694709 cites W2072114559 @default.
• W4384694709 cites W2083005649 @default.
• W4384694709 cites W2097038360 @default.
• W4384694709 cites W2106695112 @default.
• W4384694709 cites W2129453496 @default.
• W4384694709 cites W2133354058 @default.
• W4384694709 cites W2135678285 @default.
• W4384694709 cites W2140765540 @default.
• W4384694709 cites W2145150141 @default.
• W4384694709 cites W2160211542 @default.
• W4384694709 cites W2168076926 @default.
• W4384694709 cites W2401877719 @default.
• W4384694709 cites W2701735408 @default.
• W4384694709 cites W2777446764 @default.
• W4384694709 cites W2783137362 @default.
• W4384694709 cites W2938523723 @default.
• W4384694709 cites W2949133444 @default.
• W4384694709 cites W2974520132 @default.
• W4384694709 cites W2975327420 @default.
• W4384694709 cites W2975387808 @default.
• W4384694709 cites W3006111703 @default.
• W4384694709 cites W3023049665 @default.
• W4384694709 cites W3128646645 @default.
• W4384694709 cites W3134553072 @default.
• W4384694709 cites W3135119760 @default.
• W4384694709 cites W4200342220 @default.
• W4384694709 cites W4211213741 @default.
• W4384694709 doi "https://doi.org/10.3389/fendo.2023.1200932" @default.
• W4384694709 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37534207" @default.
• W4384694709 hasPublicationYear "2023" @default.
• W4384694709 type Work @default.
• W4384694709 citedByCount "0" @default.
• W4384694709 crossrefType "journal-article" @default.
• W4384694709 hasAuthorship W4384694709A5001822422 @default.
• W4384694709 hasAuthorship W4384694709A5010319430 @default.
• W4384694709 hasAuthorship W4384694709A5013208204 @default.
• W4384694709 hasAuthorship W4384694709A5036731044 @default.
• W4384694709 hasAuthorship W4384694709A5040352781 @default.
• W4384694709 hasAuthorship W4384694709A5041033720 @default.
• W4384694709 hasAuthorship W4384694709A5052434379 @default.
• W4384694709 hasAuthorship W4384694709A5062584900 @default.
• W4384694709 hasAuthorship W4384694709A5069299119 @default.
• W4384694709 hasBestOaLocation W43846947091 @default.
• W4384694709 hasConcept C121332964 @default.
• W4384694709 hasConcept C121608353 @default.
• W4384694709 hasConcept C126322002 @default.
• W4384694709 hasConcept C141071460 @default.
• W4384694709 hasConcept C142424586 @default.
• W4384694709 hasConcept C143998085 @default.
• W4384694709 hasConcept C197934379 @default.
• W4384694709 hasConcept C2776256026 @default.
• W4384694709 hasConcept C2776694085 @default.
• W4384694709 hasConcept C2777783956 @default.
• W4384694709 hasConcept C2778019345 @default.
• W4384694709 hasConcept C2778164965 @default.
• W4384694709 hasConcept C2778695046 @default.
• W4384694709 hasConcept C2778822529 @default.
• W4384694709 hasConcept C2779013556 @default.
• W4384694709 hasConcept C2779761222 @default.
• W4384694709 hasConcept C2779984678 @default.
• W4384694709 hasConcept C526584372 @default.
• W4384694709 hasConcept C71924100 @default.
• W4384694709 hasConcept C87355193 @default.
• W4384694709 hasConcept C90924648 @default.
• W4384694709 hasConceptScore W4384694709C121332964 @default.
• W4384694709 hasConceptScore W4384694709C121608353 @default.
• W4384694709 hasConceptScore W4384694709C126322002 @default.
• W4384694709 hasConceptScore W4384694709C141071460 @default.
• W4384694709 hasConceptScore W4384694709C142424586 @default.
• W4384694709 hasConceptScore W4384694709C143998085 @default.
• W4384694709 hasConceptScore W4384694709C197934379 @default.
• W4384694709 hasConceptScore W4384694709C2776256026 @default.
• W4384694709 hasConceptScore W4384694709C2776694085 @default.
• W4384694709 hasConceptScore W4384694709C2777783956 @default.

• next